Literature DB >> 24680589

Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.

Clémentine Gonthier1, Francine Walker2, Dominique Luton3, Chadi Yazbeck1, Patrick Madelenat1, Martin Koskas4.   

Abstract

OBJECTIVES: The aim of the present study was to evaluate the impact of obesity on reproductive and oncologic outcomes on the success of fertility-sparing management.
METHODS: This retrospective multicenter cohort study included women treated conservatively for atypical hyperplasia (AH) and endometrial cancer (EC) to preserve fertility. Five inclusion criteria were defined: (i) the presence of AH or grade 1 EC confirmed by two pathologists; (ii) adequate radiological examination before conservative management; (iii) available body mass index (BMI) at the beginning of treatment; and (iv) a minimum follow-up time of six months.
RESULTS: Forty patients fulfilled the inclusion criteria (17 had EC, and 23 had AH), mean age and BMI were 33 years and 29kg/m(2) respectively. Among the 15 obese patients, after medical treatment, 10 patients responded (67%) and three relapsed, whereas in the 25 non-obese patients, 19 responded (76%) and three relapsed (p=0.72). The overall pregnancy rate and follow-up time were 35% and 35 months respectively. Among the 15 obese patients, after medical treatment, two patients became pregnant, whereas in the 25 non-obese patients, 12 became pregnant (p=0.04).
CONCLUSION: Despite similar response and recurrence rates, our results suggest that fertility-sparing management for AH and EC is associated with a lower probability of pregnancy in obese patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial adenocarcinoma; Endometrial atypical hyperplasia; Fertility-sparing management; Obesity

Mesh:

Substances:

Year:  2014        PMID: 24680589     DOI: 10.1016/j.ygyno.2013.11.007

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.

Authors:  Navdeep Pal; Russell R Broaddus; Diana L Urbauer; Nyla Balakrishnan; Andrea Milbourne; Kathleen M Schmeler; Larissa A Meyer; Pamela T Soliman; Karen H Lu; Pedro T Ramirez; Lois Ramondetta; Diane C Bodurka; Shannon N Westin
Journal:  Obstet Gynecol       Date:  2018-01       Impact factor: 7.661

2.  Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.

Authors:  Marcia A Ciccone; Stephanie A Whitman; Charlotte L Conturie; Niquelle Brown; Christina E Dancz; Begum Özel; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2019-01-31       Impact factor: 2.344

Review 3.  Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.

Authors:  Qing Zhang; Gonghua Qi; Margaux J Kanis; Ruifen Dong; Baoxia Cui; Xingsheng Yang; Beihua Kong
Journal:  Oncotarget       Date:  2017-05-03

4.  Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.

Authors:  Joseph F Peevey; Brandon-Luke L Seagle; Kruti P Maniar; J Julie Kim
Journal:  Oncotarget       Date:  2017-06-27

5.  Fertility-sparing treatment in early endometrial cancer: current state and future strategies.

Authors:  Andreas Obermair; Eva Baxter; Donal J Brennan; Jessica N McAlpine; Jennifer J Muellerer; Frédéric Amant; Mignon D J M van Gent; Robert L Coleman; Shannon N Westin; Melinda S Yates; Camilla Krakstad; Monika Janda
Journal:  Obstet Gynecol Sci       Date:  2020-07-08

6.  Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis.

Authors:  Miaomiao Li; Tao Guo; Ran Cui; Ying Feng; Huimin Bai; Zhenyu Zhang
Journal:  Cancer Manag Res       Date:  2019-05-06       Impact factor: 3.602

7.  Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.

Authors:  Akira Mitsuhashi; Yuji Habu; Tatsuya Kobayashi; Yoshimasa Kawarai; Hiroshi Ishikawa; Hirokazu Usui; Makio Shozu
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

8.  A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.

Authors:  Zhibo Zhang; Huifang Huang; Fengzhi Feng; Jinhui Wang; Ninghai Cheng
Journal:  J Gynecol Oncol       Date:  2019-02-26       Impact factor: 4.401

9.  Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.

Authors:  Shannon N Westin; Bryan Fellman; Charlotte C Sun; Russell R Broaddus; Misty L Woodall; Navdeep Pal; Diana L Urbauer; Lois M Ramondetta; Kathleen M Schmeler; Pamela T Soliman; Nicole D Fleming; Jennifer K Burzawa; Alpa M Nick; Andrea M Milbourne; Ying Yuan; Karen H Lu; Diane C Bodurka; Robert L Coleman; Melinda S Yates
Journal:  Am J Obstet Gynecol       Date:  2020-08-15       Impact factor: 8.661

10.  Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia.

Authors:  Toshiya Matsuzaki; Takeshi Iwasa; Takako Kawakita; Yuri Yamamoto; Akiko Abe; Aki Hayashi; Kiyohito Yano; Masato Nishimura; Akira Kuwahara; Minoru Irahara
Journal:  Reprod Med Biol       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.